COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|
Apr. 27, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Loss Contingencies [Line Items] | |||||
| Research and development expense | $ 689,892 | $ 349,951 | $ 814,756 | $ 657,681 | |
| Joint Development and License Agreement [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Payment for research and development | $ 15,000,000 | ||||
| Issuance of initial public offering | 5,000,000 | ||||
| Non-refundable advance payment | 5,000,000 | ||||
| Unamortized advance | 4,372,070 | 4,372,070 | |||
| Research and development expense | $ 669,892 | $ 669,892 | |||
| Joint Development and License Agreement [Member] | Minimum [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Payment for research and development | 15,000,000 | ||||
| Joint Development and License Agreement [Member] | Maximum [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Payment for research and development | $ 25,000,000 | ||||
| X | ||||||||||
- Definition Non-refundable advance payment. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|